THIS CONTENT IS FREE TO ALL MEMBERSHIP LEVELS
LOGIN; or JOIN at our FREE membership level
Then enter your name, email and click download to send your content to you email

467 words

SAVE TIME! We can BROADCAST this content directly to your web site. Contact us for details. 

Search Contributor/Columnist photo gallery

Marilyn SingletonThe health professionals working day and night to care for an ever-increasing number of sick patients make me proud to be a doctor. And kudos to the grocery store workers, postal workers, police and many others who are performing essential jobs with a smile.

This is the time for positive action, not panic. For background, coronaviruses are a big family of RNA viruses named for the crown-like spikes found on their surface. They exist around the world and cause mostly upper respiratory tract infections (“common colds”) in adults. This new coronavirus is in the same family as the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) identified in humans in 2002 and Middle East Respiratory Syndrome coronavirus (MERS-CoV) identified in 2012. The CoViD-19 virus is called SARS-CoV-2 for its similarity to SARS-CoV.

While scientists are furiously experimenting with possible vaccines, the virus is sprinting from country to country despite travel restrictions. There are likely among us “healthy carriers” of the virus who have no signs or symptoms of the disease but can infect others. So, if CoViD-19 is here for a while the world has to look to effective treatments of afflicted individuals today – not a year from now. Some researchers seem to have found a strong contender.

Separate studies from a major medical centre in France and jointly from South Korea and China have found that the inexpensive, readily available anti-malarial drugs chloroquine phosphate or hydroxychloroquine are an effective treatment.

In 2004, a Belgian virologist and the U.S. Centers for Disease Control and Prevention separately found that chloroquine inhibited SARS-CoV growth in primate cells when given before or after exposure to the virus. Human trials could not be done because, thankfully, the SARS epidemic had just ended.

Fast forward to February 2019. In South Korea, these drugs were given by physicians and scientists in the CoViD-19 Central Clinical Task Force. These studies showed “certain curative effect” with “fairly good efficacy.” Further, patients treated with chloroquine demonstrated a better drop in fever, improvement of lung CT scan images, and required a shorter time to recover compared to parallel groups.

More promising is a study of 36 patients actively ill from CoViD-19 by a noted research team from France. Of the 20 patients treated with hydroxychloroquine alone, 70 per cent had no detectable virus within six days; those treated with hydroxychloroquine and azithromycin (an antibiotic with some anti-viral action) had a 100 per cent success rate. Yes, the study is small, but these are extraordinary times.

While people are struggling to pay for their next meal, we need bold action from our governments now: Approve the anti-malarial drugs chloroquine phosphate or hydroxychloroquine to fight the coronavirus.

Dr. Marilyn Singleton is a board-certified anesthesiologist. She is the immediate past President of the Association of American Physicians and Surgeons (AAPS).

© Troy Media


anti malarial drugs coronavirus CoViD-19

The views, opinions and positions expressed by columnists and contributors are the author’s alone. They do not inherently or expressly reflect the views, opinions and/or positions of our publication.

© Troy Media – All Rights Reserved
Trusted editorial content provider to media outlets across Canada
  Terms and Conditions of use

COMMUNITY NEWS OUTLET ACTION PLAN!
WEBSITE HOSTING AND ALL OUR EDITORIAL CONTENT POSTED TO YOUR SITE DAILY FOR ONLY $99.95 PER MONTH.
Contact us for details